Cartalax

Overview

Cartalax is a synthetic tetrapeptide of sequence Ala-Glu-Asp-Pro (AEDP), developed within the Khavinson short-peptide bioregulator family in the St. Petersburg Institute of Bioregulation and Gerontology. It is positioned in that research program as the cartilage-targeted peptide, complementing organ-specific peptides directed at thymus, bronchus, pineal, and other tissues.

The Khavinson research tradition proposes that each organ-derived short peptide carries a sequence-encoded regulatory signal specific to the tissue of origin. Cartalax is derived from analysis of cartilage peptide extracts and is studied in models of osteoarthritis, age-related cartilage degeneration, and chondrocyte metabolism.

Cartalax is a research compound. It is not approved as a pharmaceutical outside of specific Russian peptide preparations and is used predominantly in laboratory and preclinical contexts.

Structure / Chemistry

• Sequence: H-Ala-Glu-Asp-Pro-OH
• Three-letter notation: Ala-Glu-Asp-Pro
• Molecular formula: C18H28N4O9
• Molecular weight: approximately 444 g/mol
• Class: Linear unmodified tetrapeptide

The C-terminal proline residue introduces a conformational constraint unique among Khavinson tetrapeptides. Proline's cyclic structure restricts backbone flexibility and can protect adjacent peptide bonds from certain proteolytic enzymes, potentially extending the effective half-life relative to fully flexible sequences such as AEDG (Epithalon) or AEDL (Bronchogen).

Mechanism of Action

Within the Khavinson bioregulator framework, Cartalax is proposed to act on chondrocytes and cartilage matrix biology:

• Direct interaction with DNA regulatory regions in cartilage-derived cells, per the Khavinson model
• Modulation of chondrocyte gene expression including collagen type II, aggrecan, and matrix-remodeling enzymes
• Anti-inflammatory effects through suppression of catabolic cytokines in cartilage tissue
• Possible effects on chondrocyte proliferation and differentiation in aged or injured tissue

As with other Khavinson peptides, the proposed direct-DNA-binding mechanism remains contested outside the Khavinson research tradition. Alternative or complementary mechanisms — including receptor-mediated signaling, peptide transporter uptake, or modulation of surface proteoglycans — have not been fully characterized.

Research Summary

Most Cartalax literature appears in Russian-language bioregulator journals; independent Western-journal confirmation is limited.

Pharmacokinetics

Detailed pharmacokinetic studies of Cartalax in mainstream publications are scarce. As an unmodified tetrapeptide with a terminal proline, AEDP likely has a slightly extended plasma half-life compared to fully flexible tetrapeptides, though still short on an absolute scale — likely minutes to tens of minutes.

Research-grade use typically employs subcutaneous or intra-articular administration. The Khavinson model posits tissue-selective accumulation in cartilage; direct tracer confirmation is limited. Elimination proceeds via proteolytic degradation to free amino acids and subsequent renal clearance.

Common Discussion Topics

• Role of the C-terminal proline in sequence-level stability
• Overlap with glucosamine-, chondroitin-, and collagen-peptide joint research
• Evidence gaps in human randomized trials
• Khavinson model assumptions vs mainstream peptide pharmacology
• Research-grade purity and authentication challenges

Related Compounds

• Epithalon — pineal Khavinson tetrapeptide
• Bronchogen — bronchial Khavinson tetrapeptide
• Crystagen — thymus Khavinson tetrapeptide
• Collagen Peptides — collagen-derived joint research peptides
• BPC-157 — tissue-repair peptide with some cartilage research

Educational information only. Cartalax is a research peptide with limited independent clinical validation. This article does not constitute medical or dosing advice.